Titre :
  • Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: an EORTC-NCIC-SAKK multicenter study.
Auteur : Therasse, P. ; Mauriac, L ; Welnicka-Jaskiewicz, M ; Bruning, Peter ; Cufer, T ; Bonnefoi, H ; Tomiak, E ; Pritchard, Kathleen ; Hamilton, Andrew ; Piccart-Gebhart, Martine ; EORTC Breast Cancer and Early Clinical Studies Groups
Informations sur la publication : Journal of clinical oncology, 21, 5, (page 843-850)
Statut de publication : Publié, 2003-03
Sujet CREF : Sciences bio-médicales et agricoles
Mots-clés MeSH : Adolescent
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
Breast Neoplasms -- drug therapy
Breast Neoplasms -- economics
Breast Neoplasms -- pathology
Costs and Cost Analysis
Cyclophosphamide -- administration & dosage
Cyclophosphamide -- therapeutic use
Disease Progression
Disease-Free Survival
Dose-Response Relationship, Drug
Epirubicin -- administration & dosage
Epirubicin -- therapeutic use
Female
Filgrastim -- therapeutic use
Fluorouracil -- therapeutic use
Humans
Middle Aged
Neoadjuvant Therapy
Quality of Life
Survival Rate
Treatment Outcome
Note : Clinical Trial
Clinical Trial, Phase III
Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial
Review
SCOPUS: ar.j
Langue :
  • Anglais
Identificateurs : urn:issn:0732-183X 
info:doi/10.1200/JCO.2003.05.135
info:pmid/12610183